Abbott to Acquire Exact Sciences in $21 Billion Agreement
The deal positions Abbott to enter the US cancer screening and precision oncology diagnostics market with products including Cologuard and Oncotype DX tests.
The deal positions Abbott to enter the US cancer screening and precision oncology diagnostics market with products including Cologuard and Oncotype DX tests.
New data highlight the role of the test in further individualizing treatment decisions in early breast cancer.
Exact Sciences overcame significant obstacles to bring cancer screening innovation to patients.